A securities fraud class action filed by Hagens Berman targets Regeneron Pharmaceuticals after the company revealed protocol problems and the collapse of a Phase 3 melanoma study. The firm is seeking investors who bought REGN shares, with the class period and damages not yet disclosed.
Regeneron Pharmaceuticals faces a securities fraud class action after disclosing protocol issues and the failure of its Phase 3 melanoma trial.
Hagens Berman Sobol Shapiro LLP filed the suit and is alerting investors who bought Regeneron (NASDAQ: REGN) shares, the firm said Sept. 3. The complaint alleges the company made false and misleading statements tied to a therapy intended to treat melanoma, according to the firm's announcement.
The case follows revelations about the trial's protocol and its ultimate failure, which the firm said contradicted earlier disclosures about the program. Regeneron has not yet disclosed the trial's efficacy data, the specific protocol deviation, or whether the melanoma program will be discontinued.
The firm did not disclose the class period, the deadline for lead-plaintiff applications, or the damages sought. Regeneron's share-price reaction to the news was not immediately available.
Securities class actions of this kind typically allege violations of the antifraud provisions of the Securities Exchange Act of 1934, with investors who bought during the class period eligible to seek appointment as lead plaintiff. Regeneron, whose marketed portfolio spans the eye treatment Eylea, the immunology blockbuster Dupixent and the checkpoint inhibitor Libtayo, has treated oncology as a core growth engine.
A late-stage miss in a registrational program carries sunk development costs and delays any path to market, and securities litigation following failed trials has become a recurring risk for biopharma sponsors. The lawsuit stacks legal and regulatory exposure on top of that pipeline setback for Regeneron, whose near-term valuation leans on its ability to advance new candidates.
Investors will watch for the company's formal response to the complaint and any update on the melanoma program, with a full data presentation likely to shape both the litigation and the stock's near-term direction.
This article is for informational purposes only and does not constitute investment advice.
